What were the key financial metrics (revenue, net income, EPS) reported for the quarter ended June 30, 2025?

The brief excerpt you supplied does not include the actual financial figures—ImmuCell’s revenue, net income or earnings per share (EPS) for the quarter ended June 30 2025 are not disclosed in the text you posted. To assess the company’s performance and its impact on the stock, you’ll need to retrieve the full press release (or the accompanying earnings table) where those numbers are presented.

Trading implications (once the numbers are known):

- Revenue vs. consensus: If the reported top‑line beats analyst expectations, the stock could see a short‑term bounce on the upside, especially given ImmuCell’s niche in dairy and beef cattle health where growth trends are strong. A miss, however, may trigger a sell‑off, as the market has already priced in modest expansion.

- Net income & EPS: Positive profitability (or a narrowing loss) relative to prior quarters would reinforce the “growth‑stage” narrative and could attract momentum traders, while a widening loss would likely pressure the shares further, especially in a risk‑off environment.

- Technical context: ImmuCell has been trading in a tight range around its 52‑week low/high. A strong beat could break the upper resistance near the recent high (~$2.30) and trigger a short‑term rally; a miss could test the lower support around the recent low (~$1.80).

Actionable step: Pull the complete earnings release to confirm the exact revenue, net income and EPS figures, compare them to consensus estimates, and then align your position—long on a beat with strong momentum, or short/defensive on a miss—accordingly.